Skip to main content
Loading

Bexion Pharmaceuticals

October 18, 2023
Franciscan C
Oncology
Bexion is a clinical stage biopharmaceutical company developing a new generation of biologic therapy to treat solid tumor cancers and chemotherapy-induced peripheral neuropathy. The Company’s lead asset BXQ-350 activates Sphingolipid Metabolism and is entering into a Phase 2 trial of combination therapy in newly diagnosed metastatic colorectal cancer (mCRC) and a Phase 1 PK/PD proof of concept trial on prevention/reversal of CIPN.
Speakers
Scott Shively, CEO - Bexion Pharmaceuticals

Company Type

Privately Funded

Website

https://www.bexionpharma.com/

CEO/Top Company Official

Scott Shively

Lead Product in Development

BXQ-350

Number Of Unlicensed Products

1

BIO DOUBLE HELIX SPONSOR

BIO HELIX SPONSOR

CONFERENCE SPONSORS